Regulation of MHC Class II Expression in Glioma Cells by Class II Transactivator (CIITA)

GLIA

Volumn 45, Issue 4, 2004, Pages 392-405

  Takamura, Yukio ^a   Ikeda, Hideyuki ^a   Kanaseki, Takayuki ^a   Toyota, Minoru ^a   Tokino, Takashi ^a   Imai, Kohzoh ^a   Houkin, Kiyohiro ^a   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CIITA; Glioma; Histone acetylation; MHC class II

Indexed keywords

GAMMA INTERFERON; HISTONE ACETYLTRANSFERASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACETYLATION; ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE ACTIVATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC TRANSFECTION; GLIOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR UPREGULATION; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ADULT; AGED; CELL LINE, TUMOR; CHILD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS II; GLIOMA; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; TRANS-ACTIVATORS;

EID: 1542619547     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.10343     Document Type: Article

References (58)

1. Barbieri G, Deffrennes V, Prod'homme T, Vedrenne J, Baton F, Cortes C, Fischer A, Bono MR, Lisowska-Grospierre B, Charron D, Alcaide-Loridan C. 2002. Isoforms of the class II transactivator protein. Int Immunol 14:839-848.
2. Basta PV, Sherman PA, Ting JP. 1987. Identification of an interferon-gamma response region 5′ of the human histocompatibility leukocyte antigen DR alpha chain gene which is active in human glioblastoma multiforme lines. J Immunol 138:1275-1280.
3. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 164:3902-3912.
4. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478-480.
5. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. 1994. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365.
6. Chiari R, Hames G, Stroobant V, Texier C, Maillere B, Boon T, Coulie PG. 2000. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 60:4855-4863.
7. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol 20:17-56.
8. Colloby PS, West KP, Fletcher A. 1992. Is poor prognosis really related to HLA-DR expression by malignant melanoma cells? Histopathology 20:411-416.
9. Cresswell P. 1996. Invariant chain structure and MHC class II function. Cell 84:505-507.
10. Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy ML. 1999. The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer 85:485-491.
11. Deffrennes V, Vedrenne J, Stolzenberg MC, Piskurich J, Barbieri G, Ting JP, Charron D, Alcaide-Loridan C. 2001. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J Immunol 167:98-106.
12. Durand B, Kobr M, Reith W, Mach B. 1994. Functional complementation of major histocompatibility complex class II regulatory mutants by the purified X-box-binding protein RFX. Mol Cell Biol 14:6839-6847.
13. Gilboa E. 1999. The makings of a tumor rejection antigen. Immunity 11:263-270.
14. Goodwin BL, Xi H, Tejiram R, Eason DD, Ghosh N, Wright KL, Nagarajan U, Boss JM, Blanck G. 2001. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ 12:327-335.
15. Grunstein M. 1997. Histone acetylation in chromatin structure and transcription. Nature 389:349-352.
16. Holling TM, van der Stoep N, Quinten E, van den Elsen PJ. 2002. Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III. J Immunol 168:763-770.
17. + T cells in the antitumor immune response. J Exp Med 188:2357-2368.
18. Jabrane-Ferrat N, Fontes JD, Boss JM, Peterlin BM. 1996. Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein-protein interactions. Mol Cell Biol 16:4683-4690.
19. Kamma H, Yazawa T, Ogata T, Horiguchi H, Iijima T. 1991. Expression of MHC class II antigens in human lung cancer cells. Virchows Arch B Cell Pathol Incl Mol Pathol 60:407-412.
20. Kanaseki T, Ikeda H, Takamura Y, Toyota M, Hirohashi Y, Tokino T, Himi T, Sato N. 2003. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas. J Immunol 170:4980-4985.
21. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. 2001. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337-344.
22. Konopka G, Bonni A. 2003. Signaling pathways regulating gliomagenesis. Curr Mol Med 3:73-84.
23. Landmann S, Muhlethaler-Mottet A, Bernasconi L, Suter T, Waldburger JM, Masternak K, Arrighi JF, Hauser C, Fontana A, Reith W. 2001. Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J Exp Med 194:379-391.
24. Linhoff MW, Wright KL, Ting JP. 1997. CCAAT-binding factor NF-Y and RFX are required for in vivo assembly of a nucleoprotein complex that spans 250 base pairs: the invariant chain promoter as a model. Mol Cell Biol 17:4589-4596.
25. Liu A, Takahashi M, Toba K, Zheng Z, Hashimoto S, Nikkuni K, Furukawa T, Koike T, Aizawa Y. 1999. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells. Hematol Oncol 17:149-160.
26. Lu Y, Boss JM, Hu SX, Xu HJ, Blanck G. 1996. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction. J Immunol 156:2495-2502.
27. Lu Y, Tschickardt ME, Schmidt BJ, Blanck G. 1997. IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes. Immunol Cell Biol 75:325-332.
28. Magdinier F, Wolffe AP. 2001. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA 98:4990-4995.
29. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, Reith W. 2000. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev 14:1156-1166.
30. Morris AC, Spangler WE, Boss JM. 2000. Methylation of class II trans-activator promoter IV: a novel mechanism of MHC class II gene control. J Immunol 164:4143-4149.
31. Morris AC, Beresford GW, Mooney MR, Boss JM. 2002. Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation. Mol Cell Biol 22:4781-4791.
32. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. 1997. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 16:2851-2860.
33. Muhlethaler-Mottet A, Di Berardino W, Otten LA, Mach B. 1998. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 8:157-166.
34. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 96:8633-8638.
35. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, Suter L. 1999. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer 85:2391-2399.
36. + T cell responses in antitumor immunity. Curr Opin Immunol 10:588-594.
37. Perrin G, Schnuriger V, Quiquerez AL, Saas P, Pannetier C, de Tribolet N, Tiercy JM, Aubry JP, Dietrich PY, Walker PR. 1999. Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset. Int Immunol 11:1337-1350.
38. Piskurich JF, Wang Y, Linhoff MW, White LC, Ting JP. 1998. Identification of distinct regions of 5′ flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene. J Immunol 160:233-240.
39. Piskurich JF, Linhoff MW, Wang Y, Ting JP. 1999. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Mol Cell Biol 19:431-440.
40. Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, Cohen PA, Shu S. 2000. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6:2209-2218.
41. Richards EJ, Elgin SC. 2002. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 108:489-500.
42. Riley JL, Westerheide SD, Price JA, Brown JA, Boss JM. 1995. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA). Immunity 2:533-543.
43. Rosenberg SA. 2001. Progress in human tumour immunology and immunotherapy. Nature 411:380-384.
44. Roth W, Weller M. 1999. Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cell Mol Life Sci 56:481-506.
45. Sarcoris S, Valle MT, Barbaro AL, Tosi G, Cestari T, D'Agostino A, Megiovanni AM, Manca F, Accolla RS. 1998. HLA class II expression in uninducible hepatocarcinoma cells after transfection of A[R-1 gene product CIITA: acquisition of antigen processing and presentation capacity. J Immunol 161:814-820.
46. + T-cell activation. Glia 36:391-405.
47. Steimle V, Otten LA, Zufferey M, Mach B. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75:135-146.
48. + T cells. J Immunol 160:2896-2904.
49. Stuve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, Hirschberg DL, Brickey WJ, Soos JM, Piskurich JF, Chapman HA, Zamvil SS. 2002. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease. J Immunol 169:6720-6732.
50. Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR. 1998. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 40:151-160.
51. Ting JP, Trowsdale J. 2002. Genetic control of MHC class II expression. Cell 109(suppl):S21-33.
52. van der Stoep N, Biesta P, Quinten E, van den Elsen PJ. 2002. Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines. Int J Cancer 97:501-507.
53. Wang RF, Rosenberg SA. 1999. Human tumor antigens for cancer vaccine development. Immunol Rev 170:85-100.
54. Wong AW, Ghosh N, McKinnon KP, Reed W, Piskurich JF, Wright KL, Ting JP. 2002. Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line. J Immunol 169:3112-3119.
55. Yazawa T, Kamma H, Fujiwara M, Matsui M, Horiguchi H, Satoh H, Fujimoto M, Yokoyama K, Ogata T. 1999. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol 187:191-199.
56. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL. 2001. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842-847.
57. Zaloudik J, Moore M, Ghosh AK, Mechl Z, Rejthar A. 1988. DNA content and MHC class II antigen expression in malignant melanoma: clinical course. J Clin Pathol 41:1078-1084.
58. Zhu XS, Linhoff MW, Li G, Chin KC, Maity SN, Ting JP. 2000. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol Cell Biol 20:6051-6061.